Improved genome editing with Cas12a and Cas9 chRDNA platform in T, NK, B, andiPS cells Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR®.February 21-24,2024. High-specificity CRISPR-mediated genome engineering inanti-BCMAallogeneicCAR T cellssuppresses allograft rejection in ...
Eidell, K.P., Hemann, M.T.FAS-less allogeneic CAR T cells.Nat. Biomed. Eng8, 1518–1520 (2024). https://doi.org/10.1038/s41551-024-01319-y Download citation Published20 December 2024 Issue DateDecember 2024 DOIhttps://doi.org/10.1038/s41551-024-01319-y ...
Allogeneic CAR T cells for autoimmune diseases: a glimpse into the futuredoi:10.1038/s41392-024-01998-8Dimitrios Mougiakakoshttps://ror.org/00ggpsq73grid.5807.a0000 0001 1018 4307Department of Hematology, Oncology, and Cell TherapyOtto-von-Guericke University Magdeburg Magdeburg Germany...
If that doesn't work, please contact support so we can address the problem. In immunocompetent hosts, the ablation of FAS and CD3 in allogeneic chimeric antigen receptor T cells confers them with partial protection from rejection by T cells and natural killer cells. This is a preview of subs...
The allogeneic BCMA-targeted CAR T-cell therapy P-BCMA-ALLO1 led to high response rates in heavily pretreated patients with relapsed/refractory multiple myeloma. Patients given the regimen were also able to skip invasive apheresis, bridging therapy, and manufacturing delays, per data from...
A small but in-depth study of allogeneic CAR T cell therapy in patients with high-risk neuroblastoma shows feasibility and potential efficacy, and mechanistic insights reveal pathways to improved functionality of CAR T cells in solid tumors. This is a preview of subscription content, log in via ...
Difference is Autologous CAR T-cell therapy uses a patient's immune cells while Allogeneic CAR T-cell therapy uses donor T cells or umbilical cord...
DISCOVER ATARA Atara is an allogeneic T-cell immunotherapy company. We're harnessing the natural biology of T cells—our body’s most effective weapon in fighting disease—to develop transformative therapies for patients with cancer and autoimmune conditions. ...
We are developing allogeneic, or off-the-shelf, CAR-T cell therapies from healthy donor cells to address the limitations of currently approved therapies. View our pipeline Armored for enhanced activity We believe armoring is the key to unlocking the full potential of allogeneic cell therapies. We...
biomolecules Review Recent Advances in Allogeneic CAR-T Cells Dong Wook Kim and Je-Yoel Cho * Department of Biochemistry, BK21 PLUS Program for Creative Veterinary Science Research and Research Institute for Veterinary Science, College of Veterinary Medicine, Seoul National University, Seoul 151-742,...